Clinical Trial

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Study acronym: TEST-T-AAGN
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single-arm, open-label exploratory clinical study conducted in subjects with ANCA-associated nephritis (AAGN), aiming to evaluate the efficacy and safety of Telitacicept in the treatment of AAGN.
Trial Details
NCT Number NCT06656962
Lead Sponsor Renmin Hospital of Wuhan University
Conditions Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
Enrollment 15 participants
Start Date 2024-10-10
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-24